ISSWSH Affiliated with ISSM
Editors Welcome Submissions to Sexual Medicine Open Access
We are pleased to announce that the International Society for the Study of Women's Sexual Health (ISSWSH) is now affiliated with the ISSM.
The ISSWSH is a multidisciplinary, academic, and scientific organization with the following purposes:
To provide opportunities for communication among scholars, researchers, and practitioners about women's sexual function and sexual experience,
To support the highest standards of ethics and professionalism in research, education, and clinical practice of women's sexuality, and
To provide the public with accurate information about women's sexuality and sexual health.
We welcome ISSWSH members to the ISSM and look forward to working with our new colleagues.
Testosterone Therapy After Prostate Cancer Diagnosis
The Editorial Board of Sexual Medicine Open Access invites researchers to submit manuscripts on sexual medicine for publication.
Sexual Medicine Open Access is a quarterly peer-reviewed journal and a member of the ISSM family of journals. As an open access journal, its content can be published rapidly and reach a wide audience.
Please note that currently, Sexual Medicine Open Access does not (yet) have an impact factor (an index developed by the Institute for Scientific Information (ISI) that is used to measure the importance of an academic journal). A journal's impact factor increases as more articles in the journal receive citations. Once Sexual Medicine Open Access has published the required number of papers needed to submit an application to the ISI, an application will be sent and, it is hoped, approved quickly. The impact factor will then be applied retrospectively so that authors who publish now can note that their article appeared in a journal with an impact factor.
For more detailed information on Sexual Medicine Open Access, including its aims and scope, please click here.
American and Canadian researchers have found that testosterone replacement therapy (TRT) might be suitable for men with hypogonadism who also have a history of prostate cancer. However, more research is needed to confirm these results.
Typically, TRT is not considered safe for prostate cancer patients, as testosterone is believed to stimulate the growth of cancer cells.
In this study, scientists examined data from 149,354 men with prostate cancer. Less than 1% of the men had undergone TRT after their cancer diagnosis.
The researchers discovered that the men taking testosterone had fewer mortality events than those who were not on TRT.
They also noted that the percentage of men using TRT was low and had declined over time. Men with higher incomes and more education seemed more likely to use TRT.
The study was published online in January in the Journal of Sexual Medicine. Please click here for more details.